Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 Klebsiella pneumoniae –Producing KPC-31, a D179Y Variant of KPC-3
2021; Oxford University Press; Volume: 8; Issue: 6 Linguagem: Inglês
10.1093/ofid/ofab141
ISSN2328-8957
AutoresGiusy Tiseo, Marco Falcone, Alessandro Leonildi, Cesira Giordano, Simona Barnini, Gabriele Arcari, Alessandra Carattoli, Francesco Menichetti,
Tópico(s)Pneumonia and Respiratory Infections
ResumoA 68-year-old man had recurrent bacteremia by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae resistant to ceftazidime-avibactam and cefiderocol. The sequencing of a target region showed that it harbored a KPC-3 variant enzyme (D179Y; KPC-31), which confers resistance to ceftazidime-avibactam and restores meropenem susceptibility. The patient was successfully treated with meropenem-vaborbactam.
Referência(s)